康莱特联合MVP方案治疗晚期非小细胞肺癌临床研究

目的 比较康莱特联合MVP方案与单用MVP方案治疗晚期非小细胞肺癌的客观疗效、毒副反应及生活质量情况。方法 康莱特联合MVP方案治疗晚期非小细胞肺癌患者(联合组)16例,单用MVP方案(对照组)18例;康莱特注射液200ml静滴,在每次化疗结束后第2天应用,连用10天;MVP化疗方案:丝裂霉素(MMC)6mg/m~2VD、d_1,长春花碱酰胺(VDS)3mg/m~2VD、d_1,顺铂(PDD)25mg/m~2VD、d_(1～3),每21天为一周期。应用2周期后对两组之间的客观疗效、毒副反应及生活质量情况进行对照比较。结果 联合组客观疗效的有效率为25.0％,对照组为22.2％,两组之间比较有效率相似;联合组和对照组生活质量评定改善率+稳定率分别为81.2％、61.1％,联合组明显高于对照组;联合组的不良反应低于对照组,且发生的程度轻。结论 康莱特注射液联合化疗方案治疗晚期非小细胞肺癌,能有效地改善患者的生活质量,降低并减轻化疗不良反应。

Kanglaite (KLT) combining with MVP in the treatment of advanced non-small cell lung cancer

Objective To compare the efficacy, side effect and the improvement of life quality by the administration of Kanglaite (KLT) with MVP regimen and MVP regimen only in the treatment of non-small cell lung cancer (NSCLC). Methods Sixteen patients with NSCLC were treated by using KLT combining with MVP regimen, and eighteen patients were treated with chemotherapy. KLT was used on the second day after each chemotherapy given. MVP regimen included MMC 6mg/m2 iv drip, day 1; VDS 3mg/m2 iv drip, day 1, PDD 25mg/m2 iv drip, day 1,2,3. The treatment was recycled every 21 days. The efficacy, side effects and life quality improvement were compared after completion of drug administration only two cycles. Results Effective rate was 25. 0% in the treatment group and 22. 2% in control group. The rates were similar between the two groups. Quality of life improvement rates in treatment group and in control group were 81. 2% and 61. 1% respectively, which was higher than that in control group. Conclusions KLT in combination with MVP regimen can be used for the treatment of NSCLC. It may improve the life quality of the patients and decrease the side effect of the chemotherapy.